Skip to main content
SpringerLink
Log in
Book cover

Regional Cancer Therapy pp 379–393Cite as

Regional Therapy of Brain Tumors

  • Chapter

  • 980 Accesses

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Treatment of primary brain tumors is complicated by many factors such as resistance to conventional treatments and the susceptibility of normal brain tissue to adverse effects of therapy combined with limited capacity for repair. Malignant gliomas (anaplastic astrocytoma and Glioblastoma multiforme), the most malignant brain tumors, have a poor prognosis because of their widely invasive nature, which makes a complete resection almost impossible. The current standard first-line therapy with surgery, radiotherapy, and subsequent chemotherapy fails to control tumor growth permanently or prevent relapses, and only a small increase in survival has been achieved over the last decades, despite advances in neuroimaging, neurosurgery, radiation therapy, and chemotherapy. Treatment of malignant gliomas has therefore been among the most challenging fields in oncology for more than 20 yr and investigators have developed new innovative therapies designed to augment local tumor control.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Counsell CE, Grant R. Incidence studies of primary and secondary intracranial tumors: a systematic review of their methodology and results. J Neurooncol 1998;37:241–250.

    Article  CAS  PubMed  Google Scholar 

  2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6–29.

    CAS  PubMed  Google Scholar 

  3. Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol 1980;7: 529–541.

    Article  CAS  PubMed  Google Scholar 

  4. Lohr F, Pirzkall A, Hof H, Fleckenstein K, Debus J. Adjuvant treatment of brain metastases. Semin Surg Oncol 2001;20:50–56.

    Article  CAS  PubMed  Google Scholar 

  5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–996.

    Article  CAS  PubMed  Google Scholar 

  6. Bashir R, Hochberg F, Oot R. Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 1988;23:27–30.

    Article  CAS  PubMed  Google Scholar 

  7. Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 1992;24: 55–57.

    CAS  PubMed  Google Scholar 

  8. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg 1998;88:1–10.

    CAS  PubMed  Google Scholar 

  9. Prados MD, Levin V. Biology and treatment of malignant glioma. Semin Oncol 2000;27(3 Suppl 6): 1–10.

    CAS  PubMed  Google Scholar 

  10. Brandes AA, Fiorentino MV. The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest 1996; 14:551–559.

    CAS  PubMed  Google Scholar 

  11. Wong ET, Hess KR, Gleason M J, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572–2578.

    CAS  PubMed  Google Scholar 

  12. Hau P, Baumgart U, Pfeifer K, et al. Salvage therapy in patients with glioblastoma: is there any benefit? Cancer 2003;98:2678–2686.

    Article  PubMed  Google Scholar 

  13. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725–1731.

    CAS  PubMed  Google Scholar 

  14. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991;64:769–774.

    CAS  PubMed  Google Scholar 

  15. Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after threedimensional conformai radiotherapy. J Clin Oncol 2002;20:1635–1642.

    Article  PubMed  Google Scholar 

  16. Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 1951; 102:316–319.

    CAS  PubMed  Google Scholar 

  17. Kondziolka D, Lunsford LD, Witt TC, Flickinger JC. The future of radiosurgery: radiobiology, technology, and applications. Surg Neurol 2000;54:406–414.

    Article  CAS  PubMed  Google Scholar 

  18. Loeffler JS, Siddon RL, Wen PY, Nedzi LA, Alexander E 3rd. Stereotactic radiosurgery of the brain using a standard linear accelerator: a study of early and late effects. Radiother Oncol 1990;17:311–321.

    Article  CAS  PubMed  Google Scholar 

  19. Yamamoto M. Gammaknife radiosurgery: technology, applications, and future directions. Neurosurg Clin North Am 1999;10:181–202.

    CAS  Google Scholar 

  20. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000;47:291–298.

    Article  CAS  PubMed  Google Scholar 

  21. Chamberlain MC, Barba D, Kormanik P, Shea WM. Stereotactic radiosurgery for recurrent gliomas. Cancer 1994;74:1342–1347.

    Article  CAS  PubMed  Google Scholar 

  22. Hall WA, Djalilian HR, Sperduto PW, et al. Stereotacticradiosurgery for recurrent malignant gliomas. J Clin Oncol 1995;13:1642–1648.

    CAS  PubMed  Google Scholar 

  23. Shaw E, Scott C, Souhami L, et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol (90-05). Int J Radiat Oncol Biol Phys 1996;34:647–654.

    Article  CAS  PubMed  Google Scholar 

  24. Shrieve DC, Alexander E 3rd, Wen PY, et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 1995;36: 275–282; discussion 282-284.

    Article  CAS  PubMed  Google Scholar 

  25. Loeffler JS, Alexander E 3rd, Shea WM, et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 1992;10:1379–1385.

    CAS  PubMed  Google Scholar 

  26. Masciopinto JE, Levin AB, Mehta MP, Rhode BS. Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg 1995;82:530–535.

    CAS  PubMed  Google Scholar 

  27. Sarkaria JN, Mehta MP, Loeffler JS, et al. Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1995;32:931–941.

    Article  CAS  PubMed  Google Scholar 

  28. Mehta MP, Masciopinto J, Rozental J, et al. Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 1994;30:541–549.

    CAS  PubMed  Google Scholar 

  29. Alexander E 3rd, Loeffler JS. Radiosurgery for primary malignant brain tumors. Semin Surg Oncol 1998;14:43–452.

    Article  PubMed  Google Scholar 

  30. Curran WJ Jr, Scott CB, Weinstein AS, et al. Survival comparison of radiosurgery-eligible and-ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: areport of Radiation Therapy Oncology Group 83-02. J Clin Oncol 1993;11:857–862.

    PubMed  Google Scholar 

  31. Larson DA, Gutin PH, McDermott M, et al. Gamma knife for glioma: selection factors and survival. Int J Radiat Oncol Biol Phys 1996;36:1045–1053.

    Article  CAS  PubMed  Google Scholar 

  32. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004;60:853–860.

    Article  PubMed  Google Scholar 

  33. Scharfen CO, Sneed PK, Wara WM, et al. High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 1992;24:583–591.

    CAS  PubMed  Google Scholar 

  34. McDermott MW, Sneed PK, Gutin PH. Interstitial brachytherapy for malignant brain tumors. Semin Surg Oncol 1998; 14:79–87.

    Article  CAS  PubMed  Google Scholar 

  35. Sneed PK, Lamborn KR, Larson DA, et al. Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1996;35:37–44.

    Article  CAS  PubMed  Google Scholar 

  36. Gutin PH, Bernstein M. Stereotactic interstitial brachytherapy for malignant brain tumors. Prog Exp Tumor Res 1984;28:166–182.

    CAS  PubMed  Google Scholar 

  37. Loeffler JS, Alexander E 3rd, Hochberg FH, et al. Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys 1990;19:1455–1462.

    CAS  PubMed  Google Scholar 

  38. Sneed PK, Russo C, Scharfen CO, et al. Long-term follow-up after high-activity 125I brachytherapy for pediatric brain tumors. Pediatr Neurosurg 1996;24:314–322.

    CAS  PubMed  Google Scholar 

  39. Leibel SA, Gutin PH, Wara WM, et al. Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 1989;17:1129–1139.

    CAS  PubMed  Google Scholar 

  40. Bernstein M, Laperriere N, Glen J, Leung P, Thomason C, Landon AE. Brachytherapy for recurrent malignant astrocytoma. Int J Radiat Oncol Biol Phys 1994;30:1213–1217.

    CAS  PubMed  Google Scholar 

  41. Halligan JB, Stelzer KJ, Rostomily RC, Spence AM, Griffin TW, Berger MS. Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas. Int J Radiat Oncol Biol Phys 1996;35:541–547.

    Article  CAS  PubMed  Google Scholar 

  42. Patel S, Breneman JC, Warnick RE, et al. Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. Neurosurgery 2000;46:1123–1128; discussion 1128-1130.

    Article  CAS  PubMed  Google Scholar 

  43. Larson DA, Suplica JM, Chang SM, et al. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neurooncology 2004;6:119–126.

    Google Scholar 

  44. Gaspar LE, Zamorano LJ, Shamsa F, Fontanesi J, Ezzell GE, Yakar DA. Permanent 125iodine implants for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 1999;43:977–982.

    Article  CAS  PubMed  Google Scholar 

  45. Florell RC, Macdonald DR, Irish WD, et al. Selection bias, survival, and brachytherapy for glioma. J Neurosurg 1992;76:179–183.

    CAS  PubMed  Google Scholar 

  46. Haines SJ. Moving targets and ghosts of the past: outcome measurement in brain tumour therapy. J Clin Neurosci 2002;9:109–112.

    Article  PubMed  Google Scholar 

  47. Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998;41: 1005–1011.

    Article  CAS  PubMed  Google Scholar 

  48. Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 2002;51:343–355; discussion 355-357.

    Article  PubMed  Google Scholar 

  49. Sneed PK, Stauffer PR, McDermott MW, et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/-hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998;40:287–295.

    Article  CAS  PubMed  Google Scholar 

  50. Dempsey JF, Williams JA, Stubbs JB, Patrick TJ, Williamson JF. Dosimetric properties of a novel brachytherapy balloon applicator for the treatment of malignant brain-tumor resection-cavity margins. Int J Radiat Oncol Biol Phys 1998;42:421–429.

    Article  CAS  PubMed  Google Scholar 

  51. Tatter SB, Shaw EG, Rosenblum ML, et al. An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J Neurosurg 2003;99:297–303.

    PubMed  Google Scholar 

  52. Bigner DD, Brown MT, Friedman AH, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 1998;16:2202–2212.

    CAS  PubMed  Google Scholar 

  53. Riva P, Franceschi G, Frattarelli M, et al. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma—phase I and II study. Acta Oncol 1999;38: 351–359.

    Article  CAS  PubMed  Google Scholar 

  54. Akabani G, Cokgor I, Coleman RE, et al. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys 2000;46:947–958.

    Article  CAS  PubMed  Google Scholar 

  55. Zalutsky MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 1989;49:2807–2813.

    CAS  PubMed  Google Scholar 

  56. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD. Tenascin expression in human glioma cell lines and normal tissues. J Neuroimmunol 1992;36:41–55.

    Article  CAS  PubMed  Google Scholar 

  57. Goetz C, Riva P, Poepperl G, et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neurooncol 2003;62:321–328.

    Article  CAS  PubMed  Google Scholar 

  58. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389–1397.

    Article  CAS  PubMed  Google Scholar 

  59. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983;67:121–132.

    CAS  PubMed  Google Scholar 

  60. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980;303:1323–1329.

    Article  CAS  PubMed  Google Scholar 

  61. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011–1108.

    Article  CAS  PubMed  Google Scholar 

  62. Azizi SA, Miyamoto C. Principles of treatment of malignant gliomas in adults: an overview. J Neurovirol 1998;4:204–216.

    Article  CAS  PubMed  Google Scholar 

  63. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983;52:997–1007.

    Article  CAS  PubMed  Google Scholar 

  64. Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989;71:1–9.

    CAS  PubMed  Google Scholar 

  65. Vick NA, Khandekar JD, Bigner DD. Chemotherapy of brain tumors. Arch Neurol 1977;34:523–526.

    CAS  PubMed  Google Scholar 

  66. Forsting M, Albert FK, Kunze S, Adams HP, Zenner D, Sartor K. Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. AJNR Am J Neuroradiol 1993; 14:77–87.

    CAS  PubMed  Google Scholar 

  67. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 1996;39: 235–250; discussion 250-252.

    Article  CAS  PubMed  Google Scholar 

  68. Garfield J, Dayan AD, Weiler RO. Postoperative intracavitary chemotherapy of malignant supratentorial astrocytomas using BCNU. Clin Oncol 1975;1:213–222.

    CAS  PubMed  Google Scholar 

  69. Bosch DA, Hindmarsch T, Larsson S, Backlund EO. Intraneoplastic administration of bleomycin in intracerebral gliomas: a pilot study. Acta Neurochir Suppl (Wien) 1980;30:441–444.

    CAS  Google Scholar 

  70. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004; 100:472–479.

    CAS  PubMed  Google Scholar 

  71. Nierenberg D, Harbaugh R, Maurer LH, et al. Continuous intratumoral infusion of methotrexate for recurrent glioblastoma: a pilot study. Neurosurgery 1991;28:752–761.

    Article  CAS  PubMed  Google Scholar 

  72. Chandler WF, Greenberg HS, Ensminger WD, et al. Use of implantable pump systems for intraarterial, intraventricular and intratumoral treatment of malignant brain tumors. Ann N Y Acad Sci 1988;531:206–212.

    Article  CAS  PubMed  Google Scholar 

  73. Jacobs A, Clifford P, Kay HE. The Ommaya reservoir in chemotherapy for malignant disease in the CNS. Clin Oncol 1981;7:123–129.

    CAS  PubMed  Google Scholar 

  74. Voulgaris S, Partheni M, Karamouzis M, Dimopoulos P, Papadakis N, Kalofonos HP. Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol 2002;25:60–64.

    Article  PubMed  Google Scholar 

  75. Boiardi A, Eoli M, Salmaggi A, et al. Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. J Neurooncol 2001;54:39–47.

    Article  CAS  PubMed  Google Scholar 

  76. Patchell RA, Regine WF, Ashton P, et al. Aphase I trial of continuously infused intratumoral bleomycin for the treatment of recurrent glioblastoma multiforme. J Neurooncol 2002;60:37–42.

    Article  PubMed  Google Scholar 

  77. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The PolymerBrain Tumor Treatment Group. Lancet 1995;345:1008–1012.

    Article  CAS  PubMed  Google Scholar 

  78. Brem H, Mahaley MS Jr, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991;74:441–446.

    Article  CAS  PubMed  Google Scholar 

  79. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H. Intratumoral chemotherapy. Neurosurgery 1995;37:1128–1245.

    Article  CAS  PubMed  Google Scholar 

  80. Engelhard HH. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. Surg Neurol 2000;53:458–464.

    Article  CAS  PubMed  Google Scholar 

  81. Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D. Morbidity and survival after l,3-bis(2-chloroethyl)-l-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 1999;45:17–22; discussion 23.

    Article  CAS  PubMed  Google Scholar 

  82. McGovern PC, Lautenbach E, Brennan PJ, Lustig RA, Fishman NO. Risk factors for postcraniotomy surgical site infection after 1,3-bis (2-chloroethyl)-1-nitrosourea (Gliadel) wafer placement. Clin Infect Dis 2003;36:759–765.

    Article  CAS  PubMed  Google Scholar 

  83. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neurooncology 2003;5:79–88.

    CAS  Google Scholar 

  84. Gururangan S, Cokgor L, Rich JN, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neurooncology 2001;3:246–250.

    CAS  Google Scholar 

  85. Limentani SA, Asher A, Heafner M, Kim JW, Fraser R. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. J Neurooncol 2005;72:241–244.

    Article  CAS  PubMed  Google Scholar 

  86. Menei P, Benoit JP, Boisdron-Celle M, Fournier D, Mercier P, Guy G. Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery 1994;34:1058–1064; discussion 1064.

    Article  CAS  PubMed  Google Scholar 

  87. Menei P, Venier MC, Gamelin E, et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: a pilot study. Cancer 1999;86:325–330.

    Article  CAS  PubMed  Google Scholar 

  88. Benoit JP, Faisant N, Venier-Julienne MC, Menei P. Development of microspheres for neurological disorders: from basics to clinical applications. J Control Release 2000;65:285–296.

    Article  CAS  PubMed  Google Scholar 

  89. Koutcher JA, Alfieri AA, Thaler H, Matei C, Martin DS. Radiation enhancement by biochemical modulation and 5-fluorouracil. Int J Radiat Oncol Biol Phys 1997;39:1145–1152.

    Article  CAS  PubMed  Google Scholar 

  90. Menei P, Capelle L, Guyotat J, et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery 2005;56:242–248; discussion 248.

    Article  PubMed  Google Scholar 

  91. Menei P, Jadaud E, Faisant N, et al. Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer 2004; 100:405–410.

    Article  CAS  PubMed  Google Scholar 

  92. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995;82: 1021–1029.

    CAS  PubMed  Google Scholar 

  93. Groothuis DR, Ward S, Itskovich AC, et al. Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J Neurosurg 1999;90:321–331.

    CAS  PubMed  Google Scholar 

  94. Merlo A, Mueller-Brand J, Maecke HR. Comparing monoclonal antibodies and small peptidic hormones for local targeting of malignant gliomas. Acta Neurochir Suppl 2003;88:83–91.

    CAS  PubMed  Google Scholar 

  95. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res 1995;1:1253–1258.

    CAS  PubMed  Google Scholar 

  96. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003;88:105–111.

    CAS  PubMed  Google Scholar 

  97. Parney IF, Kunwar S, McDermott M, et al. Neuroradio graphic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 2005;102:267–275.

    CAS  PubMed  Google Scholar 

  98. Sampson JH, Akabani G, Archer GE, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003;65:27–35.

    Article  PubMed  Google Scholar 

  99. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997;3:1362–1368.

    Article  CAS  PubMed  Google Scholar 

  100. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003;65:3–13.

    Article  PubMed  Google Scholar 

  101. Engelhard HH. Gene therapy for brain tumors: the fundamentals. Surg Neurol 2000;54:3–9.

    Article  CAS  PubMed  Google Scholar 

  102. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11: 2197–2205.

    Article  CAS  PubMed  Google Scholar 

  103. Prados MD, McDermott M, Chang SM, et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J Neurooncol 2003;65:269–278.

    Article  PubMed  Google Scholar 

  104. Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11:2389–2401.

    Article  CAS  PubMed  Google Scholar 

  105. Immonen A, Vapalahti M, Tyynela K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: arandomised, controlled study. Mol Ther 2004; 10:967–972.

    Article  CAS  PubMed  Google Scholar 

  106. Rainov NG, Ren H. Oncolytic viruses for treatment of malignant brain tumours. Acta Neurochir Suppl 2003;88:113–123.

    Google Scholar 

  107. Hau. Presented at the Meeting of the American Society of Clinical Oncologists, Orlando, FL, 2002.

    Google Scholar 

  108. Wust P, Hildebrandt B, Sreenivasa G, et al. Hyperthermia in combined treatment of cancer. Lancet Oncology 2002; 3:487–497.

    Article  CAS  PubMed  Google Scholar 

  109. Jordan A, Wust P, Fahling H, John W, Hinz A, Felix R. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. Int J Hyperthermia 1993;9:51–68.

    CAS  PubMed  Google Scholar 

  110. Jordan A, Scholz R, Wust P, et al. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int J Hyperthermia 1997;13:587–605.

    Article  CAS  PubMed  Google Scholar 

  111. Jordan A, Scholz R, Maier-Hauff K, et al. Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia. J Magnetism Magn Mater 2001;225:118–126.

    Article  CAS  Google Scholar 

  112. Jordan A, Wust P, Scholz R, et al. Cellular uptake of magnetic fluid particles and their effects on human adenocarcinoma cells exposed to AC magnetic fields in vitro. Int J Hyperthermia 1996; 12:705–722.

    CAS  PubMed  Google Scholar 

  113. Jordan A, Scholz R, Maier-Hauff K, et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncl 2006;78:7–14.

    Article  CAS  Google Scholar 

  114. Gneveckow U, Jordan A, Scholz R, et al. Description and characterization of the novel hyperthermia-and thermoablation-system MFH 300F for clinical magnetic fluid hyperthermia. Med Phys 2004;31:1444–1451.

    Article  PubMed  Google Scholar 

  115. Maier-Hauff K, Rothe R, Scholz R, et al. Deep regional thermotherapy using magnetic nanoparticles: results of a feasibility study with 14 glioblastoma multiforme patients. J Neurooncol 2007;81:53–60.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center of Biomedical Nanotechnology,Department of Radiology, Berlin, Germany

    Andreas Jordan PhD

  2. Department of Neurosurgery, Bundeswehrkrankenhaus, Berlin, Germany

    Klaus Maier-Hauff MD

Authors
  1. Andreas Jordan PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Klaus Maier-Hauff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Robert-Rössle-Hospital and Tumor Institute, Charité University of Medicine, Berlin

    Peter M. Schlag MD (Professor and Head of Surgical Oncology) (Professor and Head of Surgical Oncology)

  2. Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

    Peter M. Schlag MD (Professor and Head of Surgical Oncology) & Ulrike Stein PhD (Assistant Professor) (Professor and Head of Surgical Oncology) &  (Assistant Professor)

  3. Tumor Metastasis and Therapy Response Program, Robert-Rössle-Hospital and Tumor Institute, Charité University of Medicine, Berlin

    Ulrike Stein PhD (Assistant Professor) (Assistant Professor)

  4. Erasmus University MC—Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

    Alexander M. M. Eggermont MD, PhD (Professor and Head of Surgical Oncology) (Professor and Head of Surgical Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Jordan, A., Maier-Hauff, K. (2007). Regional Therapy of Brain Tumors. In: Schlag, P.M., Stein, U., Eggermont, A.M.M. (eds) Regional Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-225-0_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-225-0_23

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-672-6

  • Online ISBN: 978-1-59745-225-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation